Clinical Trial Detail

NCT ID NCT03424005
Title A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Metastatic or Inoperable Locally Advanced Triple-Negative Breast Cancer (Morpheus-TNBC) (Morpheus-TNBC)
Recruitment Recruiting
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Hoffmann-La Roche
Indications

triple-receptor negative breast cancer

Therapies

Atezolizumab + Bevacizumab + Selicrelumab

Atezolizumab + RO6874281

Atezolizumab + Bevacizumab

Atezolizumab + Carboplatin + Gemcitabine

Atezolizumab + Eribulin

Capecitabine

Atezolizumab

Atezolizumab + Bevacizumab + Cobimetinib

Atezolizumab + Capecitabine

Atezolizumab + Ipatasertib

Atezolizumab + Ladiratuzumab vedotin

Age Groups: adult senior

No variant requirements are available.